Terlipressin Infusion Dosage
For hepatorenal syndrome-acute kidney injury (HRS-AKI), start terlipressin at 0.85 mg IV every 6 hours (Days 1-3), then assess serum creatinine on Day 4: if decreased by ≥30%, continue same dose; if decreased by <30%, increase to 1.7 mg every 6 hours; if at or above baseline, discontinue treatment. This is the FDA-approved regimen based on the pivotal CONFIRM trial 1.
Initial Dosing Strategy
The FDA-approved bolus regimen is:
- Days 1-3: 0.85 mg IV bolus every 6 hours (administered over 2 minutes via peripheral line)
- Day 4 assessment: Measure serum creatinine versus baseline
- If ≥30% decrease: Continue 0.85 mg every 6 hours
- If <30% decrease: Increase to 1.7 mg every 6 hours
- If at or above baseline: Discontinue therapy
- Duration: Continue until 24 hours after two consecutive serum creatinine values ≤1.5 mg/dL (at least 2 hours apart) or maximum 14 days 1
Alternative: Continuous Infusion
Continuous infusion is better tolerated with fewer adverse events than bolus dosing, though both are equally effective. 2 The continuous infusion regimen:
- Starting dose: 2 mg/day as continuous IV infusion
- Dose escalation: Increase every 24-48 hours up to maximum 12 mg/day until serum creatinine decreases 3
- Advantages: Lower rate of complications (35% vs 62% with bolus), effective at lower total daily doses (mean 2.23 mg/day vs 3.51 mg/day for bolus) 4
Recent evidence strongly supports continuous infusion over bolus administration. A 2016 randomized trial demonstrated significantly fewer adverse events with continuous infusion (35.29% vs 62.16%, p<0.025) while maintaining comparable efficacy (76.47% vs 64.85% response rate) 4. A 2026 meta-analysis confirmed these findings, showing continuous infusion reduces treatment failure (RR 0.32), rebleeding (RR 0.52), and total adverse events (RR 0.59) 5.
Concomitant Albumin Administration
Always administer albumin with terlipressin:
Critical caveat: Judicious albumin use is essential—excessive albumin administration increases risk of respiratory failure. Reassess volume status after 1-2 days using point-of-care ultrasonography when possible 2.
Monitoring Requirements
Terlipressin does NOT require ICU admission or central line placement 2. However:
- Continuous pulse oximetry: FDA label recommends this, though in real-world practice, vital signs (including pulse oximetry) every 2-4 hours is acceptable for patients with ACLF grade <3 2
- Do not initiate if SpO2 <90% 2
- Administer via peripheral IV line with line flush after each dose 1
Absolute Contraindications
Do not use terlipressin in:
- Serum creatinine >5 mg/dL (unlikely to benefit) 2
- Active coronary, peripheral, or mesenteric ischemia 2
- Hypoxemia (SpO2 <90%) 2
- ACLF grade 3 (use with extreme caution only in ICU setting) 2
- MELD score ≥35 in transplant-listed patients (risks may outweigh benefits) 2
Key Safety Considerations
The CONFIRM trial revealed increased respiratory failure risk (14% vs 5% placebo) and respiratory-related deaths (11% vs 2% placebo) 2, 1. This appears related to increased cardiac afterload combined with albumin volume expansion. Patients with ACLF grade 3 (≥3 organ failures) are at highest risk and require ICU monitoring if treated 2.
Practical Algorithm
- Confirm HRS-AKI diagnosis after 48 hours of diuretic withdrawal and albumin volume expansion
- Check contraindications: SpO2 ≥90%, serum creatinine ≤5 mg/dL, no active ischemia, ACLF grade <3
- Choose regimen:
- Preferred: Continuous infusion 2 mg/day (better tolerated, fewer adverse events)
- Alternative: FDA-approved bolus 0.85 mg every 6 hours
- Administer albumin: 1 g/kg day 1, then 20-40 g/day based on volume status
- Reassess Day 4: Adjust dose based on creatinine response
- Monitor: Vital signs and pulse oximetry every 2-4 hours (continuous if ACLF grade 3)
- Discontinue: 24 hours after creatinine ≤1.5 mg/dL or at 14 days maximum
The evidence clearly favors continuous infusion when available, though the FDA-approved bolus regimen remains the standard in the United States 2, 1, 4, 5.